Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is an increased risk of opportunistic infections in patients with PsA, and this risk is increased further with targeted biologic therapy.<b>Areas covered</b>: This paper reviews the role of the interleukin (IL)-12, IL-23 and IL-17 axis in the pathogenesis of PsA.
|
31847608 |
2020 |
Arthritis, Psoriatic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In comparison with PsA, AA was associated with higher levels of IL-17F, IL-17E and IL-23.
|
30980732 |
2020 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic associations imply a role for CD8+ T cells and the IL-23/IL-17 axis in psoriatic arthritis (PsA) and other spondyloarthritides (SpA).
|
31677365 |
2020 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, these cells likely to be a part of the IL-23/IL-17A cytokine network and play a critical role in the pathogenesis of PsA.
|
31541902 |
2020 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite a ballooning therapeutic tool box, treatment responses to newer biologic agents and oral small molecules in psoriatic arthritis (PsA) and spondyloarthritis (SpA) are of similar magnitude to those observed with anti-Tumor Necrosis Factor (TNF) medications (1, 2).The PsA and SpA therapeutic outcomes stand in marked contrast to those reported in psoriasis where blockade of molecules in the IL-23/IL-17 pathway often provide prolonged, deep responses and in some cases even remission (3).
|
31736273 |
2020 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-23 is important in the proliferation and maintenance of IL-17, and therefore, cytokines of the IL-23/IL-17 axis attracted much interest as therapeutic targets in psoriasis and PsA.
|
31447673 |
2019 |
Arthritis, Psoriatic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association to PsA was observed in the presence of polymorphisms: TNF-238 G > A (rs361525), -308 G > A (rs1800629), and -857 C > T (rs1799724); IL12B C > G (rs6887695) and A > C (rs3212227); IL23A A > G (rs2066808) and IL23R G > A (rs11209026).
|
30584776 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical trials have reported the effectiveness of numerous biologics with different targets, such as tumor necrosis factor-α, interleukin (IL)-17A, IL-17 receptor, IL-12/23(p40), and IL-23(p19) for the treatment of PsA.
|
30891646 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the levels of the proinflammatory cytokines tumor necrosis factor α (TNF-α), interleukin 23 (IL-23) and IL-17 in patients with psoriasis and psoriatic arthritis with concomitant metabolic syndrome.
|
30858782 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, these Ad.scIL-23-treated mice represent a physiologically relevant model of psoriatic arthritis for understanding disease progression and for testing therapeutic approaches.-Flores, R. R., Carbo, L., Kim, E., Van Meter, M., De Padilla, C. M. L., Zhao, J., Colangelo, D., Yousefzadeh, M. J., Angelini, L. A., Zhang, L., Pola, E., Vo, N., Evans, C. H., Gambotto, A., Niedernhofer, L. J., Robbins, P. D. Adenoviral gene transfer of a single-chain IL-23 induces psoriatic arthritis-like symptoms in NOD mice.
|
31170010 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
In recent years, interleukin (IL)-12/IL-23 inhibitors have entered clinical practice as a new class of drug for the treatment of PsA, with some data suggesting a lower effect of body weight on their effectiveness.
|
31264033 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin-17A (IL-17A), IL-17F, IL-23, and CRP concentrations were measured in serum samples collected as part of the 2 PSUMMIT phase III studies of ustekinumab in PsA (n = 927).
|
31070869 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two independent authors searched the databases PubMed and EMBASE for studies reporting on adverse events in phase 3 trials of IL-17 and IL-23 inhibitors for patients with psoriasis and psoriatic arthritis.
|
31721310 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we will discuss recent advances on the cellular and molecular pathophysiological mechanisms that regulate the initiation and progression of PsA as well as new therapeutic approaches for IL-23/IL-23R targeted therapeutics.
|
30196070 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The IL-23/Th17 axis has been implicated in the development of autoimmune diseases, such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
|
29148561 |
2018 |
Arthritis, Psoriatic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the study, a higher level of IL-17 and IL-23 was also shown in patients with psoriatic arthritis in comparison to patients with normal psoriasis.
|
30206447 |
2018 |
Arthritis, Psoriatic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study we show that psoriatic arthritis (PsA), a severe disease of the joints depending on the activation of the IL-23/IL-17 pathway, is characterized by a skewed ILC homeostasis.
|
29330320 |
2018 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.
|
30172115 |
2018 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Perturbation of the IL-23/Th17 axis instigates Th17-mediated inflammation in R26Stat3C<sup>stopfl/fl</sup> CD4Cre mice, leading to cutaneous and synovio-entheseal inflammation and bone pathologic features highly reminiscent of human PsA.
|
29439292 |
2018 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The IL-23/IL-17 axis is central to the pathogenesis of psoriatic arthritis (PsA).
|
29148410 |
2018 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The unique bone phenotype that occurs in PsA and AS is a surprising coexistence of both systemic bone loss and periosteal and entheseal bone formation and is likely to be the result of the actions of IL-23 and/or IL-17 on bone.
|
30266977 |
2018 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The IL-23/IL-17 axis plays a critical pathogenic role for both PsA and Ps, and biologics neutralizing IL-17A or IL-23/IL-12 are effective therapies for PsA and Ps.
|
27666819 |
2017 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cytokines interleukin (IL)-12 and IL-23 have been involved in the pathogenesis of psoriasis and psoriatic arthritis.
|
28441904 |
2017 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, polymorphisms of <i>IL23R</i> are a risk factor for ankylosing spondylitis (AS) and psoriatic arthritis (PsA), which indicates that IL-23 is also involved in the pathogenesis of spondyloarthritis (SpA).
|
28850053 |
2017 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Psoriatic arthritis (PsA) can be treated using biologic therapies targeting biomolecules such as tumor necrosis factor alpha, interleukins (IL)-17 and IL-23.
|
26108918 |
2016 |